Interactions between antiepileptics and second-generation antipsychotics

被引:68
|
作者
de Leon, Jose [1 ,3 ]
Santoro, Vincenza [2 ]
D'Arrigo, Concetta [2 ]
Spina, Edoardo [2 ]
机构
[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Messina, Italy
[3] Univ Granada, Inst Neurosci Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
关键词
amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; carbamazepine; clozapine; drug interactions; eslicarbazepine; ethosuximide; felbamate; gabapentin; iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; pharmacokinetics; phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; rufinamide; stiripentol; tiagabine; topiramate; valproate; vigabatrin; ziprasidone; zonisamide; STEADY-STATE PHARMACOKINETICS; DRUG-MONITORING SERVICE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; OLANZAPINE SERUM CONCENTRATIONS; MAJOR DEPRESSIVE DISORDER; PREGNANE-X RECEPTOR; BIPOLAR I DISORDER; OF-THE-LITERATURE; VALPROIC ACID;
D O I
10.1517/17425255.2012.660918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED--SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. Areas covered: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED--SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (1500 mg/day) or topiramate (>= 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED--SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
引用
收藏
页码:311 / 334
页数:24
相关论文
共 50 条
  • [41] Are Second-Generation Antipsychotics Useful in Tardive Dystonia?
    Pinninti, Narsimha Reddy
    Faden, Justin
    Adityanjee, Adit
    CLINICAL NEUROPHARMACOLOGY, 2015, 38 (05) : 183 - 197
  • [42] Switching Between Second-Generation AntipsychoticsWhy and How?
    Monika Edlinger
    Susanne Baumgartner
    Nadja Eltanaihi-Furtmüller
    Martina Hummer
    W. Wolfgang Fleischhacker
    CNS Drugs, 2005, 19 : 27 - 42
  • [43] Use of second-generation antiepileptic drugs in the pediatric population
    Chung A.M.
    Eiland L.S.
    Pediatric Drugs, 2008, 10 (4) : 217 - 254
  • [44] Dysregulation of Adipocytokines Related to Second-Generation Antipsychotics in Normal Fasting Glucose Patients With Schizophrenia
    Sugai, Takuro
    Suzuki, Yutaro
    Fukui, Naoki
    Ono, Shin
    Watanabe, Junzo
    Tsuneyama, Nobuto
    Someya, Toshiyuki
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (03) : 390 - 393
  • [45] Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
    Erik Johnsen
    Rune A Kroken
    Tore Wentzel-Larsen
    Hugo A Jørgensen
    BMC Psychiatry, 10
  • [46] Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study
    Najar, H.
    Joas, E.
    Kardell, M.
    Palsson, E.
    Landen, M.
    ACTA PSYCHIATRICA SCANDINAVICA, 2017, 135 (06) : 606 - 611
  • [47] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
    Lik Hang N. Lee
    Charles Choi
    Abby C. Collier
    Alasdair M. Barr
    William G. Honer
    Ric M. Procyshyn
    CNS Drugs, 2015, 29 : 975 - 983
  • [48] Second-Generation Antipsychotics During the Lactation Period A Comparative Systematic Review on Infant Safety
    Uguz, Faruk
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (03) : 244 - 252
  • [49] Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naive French Canadian Patients
    Roy, Genevieve
    Bedard, Alain
    Desmarais, Paul-Andre
    Jourdain, France
    Allen, Sylvie
    Michaud, Danielle
    Ben Amor, Leila
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2010, 20 (06) : 479 - 487
  • [50] Second-Generation Antipsychotics and Suicide: A Commentary
    Zuschlag, Zachary D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (05)